Disease hub

Glioblastoma

Canti combines public evidence about glioblastoma across diseases, targets, drugs, clinical trials and regulatory sources in one typed evidence graph. Source provenance is preserved so researchers and clinicians can inspect how each relationship was derived.

Off-label and drug-repurposing leads may appear for expert discussion—not as treatment recommendations. A trial, association or regulatory record does not establish clinical benefit.

Source catalogue

7333

Imported rows

6283

Explorer-eligible

1287

Targets w/ drugs

465

Explore evidence

Identifiers, aliases & guided lookup

Disease identifiers & aliases

Common aliases: GBM · glioblastoma multiforme · MONDO_0018177

Historical terminology: WHO grade IV · grade IV astrocytoma

Ontology identifiers: MONDO_0018177

Source labels: Open Targets: glioblastoma

Some historical labels may not reflect current WHO classification.

Open guided evidence lookup

Important limitations

This page is an evidence-navigation tool, not a treatment plan: associations, trials, approvals elsewhere, and shared targets do not establish safety or clinical benefit in glioblastoma.
Some relationships or approvals may not yet be indexed or normalized; terminated and withdrawn trials remain visible for transparency.

Evidence coverage

Source catalogue associations: 7,333
Explorer-eligible targets: 1,287
Targets with drug relationships: 465
Disease-linked drugs: 452
Imported evidence rows: 6,283

How coverage is calculated

Catalogue associations are external source-universe counts for this disease node — not a validated or treatment-linked inventory.

Imported rows count source evidence rows, not unique targets or drugs.

Explorer eligibility reflects current evidence-graph entities available in the ranked explorer.

Drug-linked targets and disease-linked drugs are distinct linked entities in Canti.

Disease-drug evidence edges: 769. Counts may use different denominators and should not be divided into a coverage percentage.

Explore ranked targets Explore drugs Explore trials

GBM Evidence Graph explorer

Server-paginated cross-filter for EFO_0000519. Association score ranks disease–target evidence (higher = stronger catalogue association). Tiers A–D summarize score/evidence bands. Drug phase values are scoped to Glioblastoma evidence edges — not global development status or approval. Requires oncology review — not a care plan.

Linked drugs

769

Linked targets

1287

Mechanisms

—

Trials

—

Evidence sources

Relationship type

TierPhase in GlioblastomaStatusSourceAction typeTarget class

Targets

Showing 0 of 0

Page 1 of 1

Drugs (ranked GBM disease–drug)

Showing 0 of 0

Page 1 of 1

Mechanism of action

Drug	Target	Mechanism	Action	Class	Source
Select a target, drug, or MoA facet to load mechanism links.

Trials

NCT IDs derived from disease–drug source URLs; titles/status and trial phase enriched from clinical_trials when present. Trial phase is never copied from the disease–drug aggregate. Search URLs are labelled separately from canonical study links.

Study	Title	Drug	Trial phase	Status	Link
Select a target or drug to load linked trial summaries.

Graph-derived rankings

Compact server aggregates over active edges. Counts are graph connectivity — not efficacy or clinical priority.

Shared-target drugs

Graph-derived · not a biological claim

—

Page 1 of 1

Multi-target drugs

Graph-derived · not a biological claim

—

Page 1 of 1

Targets with most linked drugs

Graph-derived · not a biological claim

—

Page 1 of 1

Drugs with most trials

Graph-derived · not a biological claim

—

Page 1 of 1

Disease-aware regulatory approval

Regulator-backed indication status for Glioblastoma. Trial phase is not approval.

temozolomide

Regulatory status for Glioblastoma

Approved for Glioblastoma

bevacizumab

Regulatory status for Glioblastoma

Approved for Glioblastoma

everolimus

Regulatory status for Glioblastoma

Off-label for Glioblastoma

Approved for:

Breast cancer · EMA · ema

Approved for another indication · EMA · ema

Currently indexed off-label and cross-indication drug evidence

Complete paths only — grouped by drug.

Showing 133 of 232 complete cross-indication paths · 10 of 61 drugs shown

10 of 61 drugs

Approved diseaseTargetRelationship typeRegulator / source

BORTEZOMIB (CHEMBL325041)
Drug details
Off-label for glioblastoma
Approved elsewhere: Multiple myeloma
Connected through: ADRM1 · direct moa; PSMA1 · direct moa; PSMA2 · direct moa; PSMA3 · direct moa; PSMA4 · direct moa; PSMA5 · direct moa; PSMA6 · direct moa; PSMA7 · direct moa; PSMA8 · direct moa; PSMB1 · direct moa; PSMB10 · direct moa; PSMB11 · direct moa; PSMB2 · direct moa; PSMB3 · direct moa; PSMB4 · direct moa; PSMB5 · direct moa; PSMB6 · direct moa; PSMB7 · direct moa; PSMB8 · direct moa; PSMB9 · direct moa; PSMC1 · direct moa; PSMC2 · direct moa; PSMC3 · direct moa; PSMC4 · direct moa; PSMC5 · direct moa; PSMC6 · direct moa; PSMD1 · direct moa; PSMD11 · direct moa; PSMD12 · direct moa; PSMD13 · direct moa; PSMD14 · direct moa; PSMD2 · direct moa; PSMD3 · direct moa; PSMD4 · direct moa; PSMD6 · direct moa; PSMD7 · direct moa; PSMD8 · direct moa; SEM1 · direct moa
Regulator / provenance: EMA
Complete paths for this drug: 38
Related trials
DEPATUXIZUMAB MAFODOTIN (CHEMBL3707277)
Drug details
Off-label for glioblastoma
Approved elsewhere: Multiple myeloma
Connected through: EGFR · direct moa; TUBA1A · direct moa; TUBA1B · direct moa; TUBA1C · direct moa; TUBA3C · direct moa; TUBA3E · direct moa; TUBA4A · direct moa; TUBB · direct moa; TUBB1 · direct moa; TUBB2A · direct moa; TUBB2B · direct moa; TUBB3 · direct moa; TUBB4A · direct moa; TUBB4B · direct moa; TUBB6 · direct moa; TUBB8 · direct moa
Regulator / provenance: FDA
Complete paths for this drug: 16
Related trials
CABAZITAXEL (CHEMBL1201748)
Drug details
Off-label for glioblastoma
Approved elsewhere: Prostate cancer
Connected through: TUBA1A · direct moa; TUBA1B · direct moa; TUBA1C · direct moa; TUBA3C · direct moa; TUBA3E · direct moa; TUBA4A · direct moa; TUBB · direct moa; TUBB1 · direct moa; TUBB2A · direct moa; TUBB2B · direct moa; TUBB3 · direct moa; TUBB4A · direct moa; TUBB4B · direct moa; TUBB6 · direct moa; TUBB8 · direct moa
Regulator / provenance: EMA
Complete paths for this drug: 15
Related trials
PANOBINOSTAT (CHEMBL483254)
Drug details
Off-label for glioblastoma
Approved elsewhere: Multiple myeloma
Connected through: HDAC1 · direct moa; HDAC10 · direct moa; HDAC11 · direct moa; HDAC2 · direct moa; HDAC3 · direct moa; HDAC4 · direct moa; HDAC5 · direct moa; HDAC6 · direct moa; HDAC7 · direct moa; HDAC8 · direct moa; HDAC9 · direct moa
Regulator / provenance: EMA
Complete paths for this drug: 11
Related trials
PAZOPANIB (CHEMBL477772)
Drug details
Off-label for glioblastoma
Approved elsewhere: Renal cell carcinoma
Connected through: CSF1R · direct moa; FGFR1 · direct moa; FGFR3 · direct moa; FLT1 · direct moa; FLT4 · direct moa; ITK · direct moa; KDR · direct moa; KIT · direct moa; LCK · direct moa; PDGFRA · direct moa; PDGFRB · direct moa
Regulator / provenance: FDA
Complete paths for this drug: 11
Related trials
NINTEDANIB (CHEMBL502835)
Drug details
Off-label for glioblastoma
Approved elsewhere: Non-small cell lung carcinoma
Connected through: FGFR1 · direct moa; FGFR2 · direct moa; FGFR3 · direct moa; FGFR4 · direct moa; FLT1 · direct moa; FLT4 · direct moa; KDR · direct moa; PDGFRA · direct moa; PDGFRB · direct moa
Regulator / provenance: EMA
Complete paths for this drug: 9
Related trials
SORAFENIB (CHEMBL1336)
Drug details
Off-label for glioblastoma
Approved elsewhere: Hepatocellular carcinoma
Connected through: BRAF · direct moa; FLT1 · direct moa; FLT3 · direct moa; FLT4 · direct moa; KDR · direct moa; KIT · direct moa; PDGFRB · direct moa; RAF1 · direct moa; RET · direct moa
Regulator / provenance: FDA
Complete paths for this drug: 9
Related trials
SORAFENIB TOSYLATE (CHEMBL1200485)
Drug details
Off-label for glioblastoma
Approved elsewhere: Hepatocellular carcinoma
Connected through: BRAF · direct moa; FLT1 · direct moa; FLT3 · direct moa; FLT4 · direct moa; KDR · direct moa; KIT · direct moa; PDGFRB · direct moa; RAF1 · direct moa; RET · direct moa
Regulator / provenance: FDA
Complete paths for this drug: 9
Related trials
SUNITINIB (CHEMBL535)
Drug details
Off-label for glioblastoma
Approved elsewhere: Renal cell carcinoma
Connected through: CSF1R · direct moa; FLT1 · direct moa; FLT3 · direct moa; FLT4 · direct moa; KDR · direct moa; KIT · direct moa; PDGFRA · direct moa; PDGFRB · direct moa; RET · direct moa
Regulator / provenance: EMA
Complete paths for this drug: 9
Related trials
CRIZOTINIB (CHEMBL601719)
Drug details
Off-label for glioblastoma
Approved elsewhere: Non-small cell lung carcinoma
Connected through: ALK · direct moa; EML4 · direct moa; MET · direct moa; MST1R · direct moa; NPM1 · direct moa; ROS1 · direct moa
Regulator / provenance: FDA
Complete paths for this drug: 6
Related trials

10 of 61 drugs

Approval in another disease and a shared target or biomarker do not establish safety or clinical benefit in glioblastoma.

Trial summary

Open trial status does not mean eligibility or suitability. Review with oncology team. Full lists and filters live on the trials surface.

Open/active: 154Completed (status indexed): 440Completed with indexed results: not available on this summaryStopped/withdrawn: 151View trials

Source connectorsCollapsed · expand for provenance badges

Requires oncology review — empty groups mean no matching rows in this load window, not a claim about biology or clinical use.

No source badges for loaded rows

When Open Targets, ChEMBL, ClinicalTrials.gov, or similar imports exist for this hub, connector badges appear here.

View research signals

Data sources & freshness

View sources and freshnessHide sources and freshness8 connected sources · 0 current · 1 delayed · 7 stale · 0 failedSome source imports need refresh.

Freshness indicates Canti’s latest successful import, not necessarily the source publisher’s latest release. Some imports are bounded or manually reviewed rather than full-catalogue synchronizations.

Canti deterministic signal builder Stale — Derived research signals · 16 May 2026, 13:43 UTC · Bounded import. Latest successful import needs refresh.
ChEMBL Stale — Drug identities and target mechanisms · 16 May 2026, 13:43 UTC · Bounded import. Latest successful import needs refresh.
ClinicalTrials.gov (materialized) Stale — Trials, interventions and disease links · 22 Jul 2026, 12:31 UTC · Bounded import. Latest successful import needs refresh.
DailyMed Stale — US product labels · 23 Jul 2026, 14:47 UTC · Bounded import. Latest successful import needs refresh.
EMA Stale — European regulatory evidence · 23 Jul 2026, 14:47 UTC · Bounded import. Latest successful import needs refresh.
FDA / openFDA / Drugs@FDA Stale — US regulatory evidence · 23 Jul 2026, 14:47 UTC · Bounded import. Latest successful import needs refresh.
Open Targets Platform Stale — Disease–target associations · 17 Jul 2026, 14:28 UTC · Bounded import. Latest successful import needs refresh.
repoDB-style disease–drug import Delayed — Repurposing evidence · 16 May 2026, 19:19 UTC · Manual import. Latest successful import is older than the expected cadence.